Tools
Tools
Hellmich, Bernhard, Agueda, Ana, Monti, Sara, Buttgereit, Frank, de Boysson, Hubert, Brouwer, Elisabeth, Cassie, Rebecca, Cid, Maria C., Dasgupta, Bhaskar, Dejaco, Christian, Hatemi, Gulen, Hollinger, Nicole, Mahr, Alfred, Mollan, Susan P., Mukhtyar, Chetan 
ORCID: https://orcid.org/0000-0002-9771-6667, Ponte, Cristina, Salvarani, Carlo, Sivakumar, Rajappa, Tian, Xinping, Tomasson, Gunnar, Turesson, Carl, Schmidt, Wolfgang, Villiger, Peter M., Watts, Richard, Young, Chris and Luqmani, Raashid Ahmed
(2020)
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Annals of the Rheumatic Diseases, 79 (1).
pp. 19-30.
ISSN 0003-4967
Abstract
BACKGROUND: Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. METHODS: Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. RESULTS: Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. CONCLUSIONS: We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.
| Item Type: | Article |
|---|---|
| Additional Information: | © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. |
| Uncontrolled Keywords: | eular recommendations,takayasu arteritis,giant cell arteritis,large vessel vasculitis,management,immunology and allergy,rheumatology,immunology,biochemistry, genetics and molecular biology(all) ,/dk/atira/pure/subjectarea/asjc/2700/2723 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Epidemiology and Public Health Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 27 Nov 2019 02:00 |
| Last Modified: | 29 Jan 2024 02:34 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/73108 |
| DOI: | 10.1136/annrheumdis-2019-215672 |
Actions (login required)
 |
View Item |